Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy

Journal of Cardiac Failure

Volumn 18, Issue 10, 2012, Pages 804-809

  Witteles, Ronald M ^a   Keu, Khun Visith ^b   Quon, Andrew ^b   Tavana, Homa ^a   Fowler, Michael B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glucose metabolism; Heart failure; insulin resistance

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN; SITAGLIPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART MUSCLE; HUMAN; MALE; NONISCHEMIC CARDIOMYOPATHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD GLUCOSE; CARDIOMYOPATHY, DILATED; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIUM; PYRAZINES; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TRIAZOLES;

EID: 84867184529     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.07.009     Document Type: Article

References (55)

1. M.M. Engelgau, L.S. Geiss, J.B. Saaddine, J.P. Boyle, S.M. Benjamin, and E.W. Gregg The evolving diabetes burden in the United States Ann Int Med 140 2004 945 950
2. National diabetes fact sheet, 2011. Available at http://www.cdc.gov/ diabetes/pubs/pdf/ndfs-2011.pdf. Accessed May 15, 2012.
3. L.S. Geiss, W.H. Herman, and P.J. Smith Mortality among persons with non-insulin depndent diabetes P.H. Bennett, Diabetes in America 2nd ed 1995 National Institutes of Health Bethesda, MD 233 258
4. P.W. Wilson, and W.B. Kannel Obesity, diabetes, and risk of cardiovascular disease in the elderly Am J Geriatr Cardiol 11 2002 119 125
5. W.B. Kannel, and D.L. McGee Diabetes and cardiovascular disease. The Framingham study JAMA 241 1979 2035 2038
6. C. Bauters, N. Lamblin, E.P. Mc Fadden, E. van Belle, A. Millaire, and P. de Groote Influence of diabetes mellitus on heart failure risk and outcome Cardiovasc Diabetol 2 2003 1
7. L. Amato, G. Paolisso, F. Cacciatore, N. Ferrara, P. Ferrara, S. Canonico Osservatorio Geriatrico Regione Campania Group Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly Diabetes Metab 23 1997 213 218
8. J. Arnlov, L. Lind, B. Zethelius, B. Andren, C.N. Hales, and B. Vessby Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up Am Heart J 142 2001 720 724
9. A.G. Bertoni, A. Tsai, E.K. Kasper, and F.L. Brancati Diabetes and idiopathic cardiomyopathy: a nationwide case-control study Diabetes Care 26 2003 2791 2795
10. S.S. Coughlin, D.L. Pearle, K.L. Baughman, A. Wasserman, and M.C. Tefft Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study Ann Epidemiol 4 1994 67 74
11. J.S. Gottdiener, A.M. Arnold, G.P. Aurigemma, J.F. Polak, R.P. Tracy, and D.W. Kitzman Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study J Am Coll Cardiol 35 2000 1628 1637
12. J. He, L.G. Ogden, L.A. Bazzano, S. Vupputuri, C. Loria, and P.K. Whelton Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study Arch Int Med 161 2001 996 1002
13. A. Ilercil, R.B. Devereux, M.J. Roman, M. Paranicas, M.J. O'Grady, and E.T. Lee Associations of insulin levels with left ventricular structure and function in American Indians: the Strong Heart study Diabetes 51 2002 1543 1547
14. E. Ingelsson, J. Arnlov, L. Lind, and J. Sundstrom Metabolic syndrome and risk for heart failure in middle-aged men Heart 92 2006 1409 1413
15. E. Ingelsson, J. Sundstrom, J. Arnlov, B. Zethelius, and L. Lind Insulin resistance and risk of congestive heart failure JAMA 294 2005 334 341
16. C. Iribarren, A.J. Karter, A.S. Go, A. Ferrara, J.Y. Liu, and S. Sidney Glycemic control and heart failure among adult patients with diabetes Circulation 103 2001 2668 2673
17. A. Shah, and R.P. Shannon Insulin resistance in dilated cardiomyopathy Rev Cardiovasc Med 4 Suppl 6 2003 S50 S57
18. N. Suskin, R.S. McKelvie, R.J. Burns, R. Latini, D. Pericak, and J. Probstfield Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur Heart J 21 2000 1368 1375
19. J.W. Swan, S.D. Anker, C. Walton, I.F. Godsland, A.L. Clark, and F. Leyva Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 1997 527 532
20. R.M. Witteles, and M.B. Fowler Cardiomyopathy of insulin resistance Heart Fail Clin 2 2006 13 23
21. R.M. Witteles, and M.B. Fowler Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options J Am Coll Cardiol 51 2008 93 102
22. R.M. Witteles, W.H. Tang, A.H. Jamali, J.W. Chu, G.M. Reaven, and M.B. Fowler Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link J Am Coll Cardiol 44 2004 78 81
23. H. Taegtmeyer Switching metabolic genes to build a better heart Circulation 106 2002 2043 2045
24. V.G. Davila-Roman, G. Vedala, P. Herrero, L. de las Fuentes, J.G. Rogers, and D.P. Kelly Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy J Am Coll Cardiol 40 2002 271 277
25. M.A. Martin, M.A. Gomez, F. Guillen, B. Bornstein, Y. Campos, and J.C. Rubio Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure Biochim Biophys Acta 1502 2000 330 336
26. P. Razeghi, M.E. Young, J.L. Alcorn, C.S. Moravec, O.H. Frazier, and H. Taegtmeyer Metabolic gene expression in fetal and failing human heart Circulation 104 2001 2923 2931
27. H. Taegtmeyer, P. McNulty, and M.E. Young Adaptation and maladaptation of the heart in diabetes: part I: general concepts Circulation 105 2002 1727 1733
28. Y. Guan, C. Hao, D.R. Cha, R. Rao, W. Lu, and D.E. Kohan Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat Med 11 2005 861 866
29. P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, and N.P. Jones Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 357 2007 28 38
30. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, and E.S. Horton Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003 Circulation 108 2003 2941 2948
31. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
32. D.P. Kao, R.M. Witteles, A. Quon, J.C. Wu, S.S. Gambhir, and M.B. Fowler Rosiglitazone increases myocardial glucose metabolism in insulin-resistant cardiomyopathy J Am Coll Cardiol 55 2010 926 927
33. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
34. S.L. Bacharach, J.J. Bax, J. Case, D. Delbeke, K.A. Kurdziel, and W.H. Martin PET myocardial glucose metabolism and perfusion imaging: part 1 - guidelines for data acquisition and patient preparation J Nucl Cardiol 10 2003 543 556
35. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
36. M. Salehi, and D.A. d'Alessio New therapies for type 2 diabetes based on glucagon-like peptide 1 Cleve Clin J Med 73 2006 382 389
37. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
38. B.P. Bullock, R.S. Heller, and J.F. Habener Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 137 1996 2968 2978
39. M. Lenski, A. Kazakov, N. Marx, M. Bohm, and U. Laufs Effects of DPP-4 inhibition on cardiac metabolism and function in mice J Mol Cell Cardiol 51 2011 906 918
40. S. Ravassa, A. Zudaire, and J. Diez GLP-1 and cardioprotection. From bench to bedside Cardiovasc Res 94 2012 316 323
41. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett 358 1995 219 224
42. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
43. M.H. Davidson Cardiovascular effects of glucagonlike peptide-1 agonists Am J Cardiol 108 2011 33B 41B
44. R. Gros, X. You, L.L. Baggio, M.G. Kabir, A.M. Sadi, and I.N. Mungrue Cardiac function in mice lacking the glucagon-like peptide-1 receptor Endocrinology 144 2003 2242 2252
45. T. Matsui, J. Tao, F. del Monte, K.H. Lee, L. Li, and M. Picard Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo Circulation 104 2001 330 335
46. L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, and L. Zourelias Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 110 2004 955 961
47. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
48. T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, and Y.T. Shen Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J Pharmacol Exp Ther 317 2006 1106 1113
49. R. Nielsen, H. Wiggers, and M. Halbirk Metabolic effects of short-term GLP-1 treatment in insulin resistant heart failure patients Exp Clin Endocrinol Diabetes 120 2012 266 272
50. H.C. Ku, W.P. Chen, and M.J. Su GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats Naunyn-Schmiedeberg Arch Pharmacol 382 2010 463 474
51. H.C. Ku, W.P. Chen, and M.J. Su DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion Naunyn-Schmiedeberg Arch Pharmacol 384 2011 197 207
52. M. Sauve, K. Ban, M.A. Momen, Y.Q. Zhou, R.M. Henkelman, and M. Husain Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice Diabetes 59 2010 1063 1073
53. G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, and M. Pala A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure J Am Coll Cardiol 48 2006 992 998
54. L. Lee, R. Campbell, M. Scheuermann-Freestone, R. Taylor, P. Gunaruwan, and L. Williams Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment Circulation 112 2005 3280 3288
55. L. Zhang, Y. Lu, H. Jiang, L. Zhang, A. Sun, and Y. Zou Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis J Am Coll Cardiol 59 2012 913 922